{"id":239739,"date":"2026-06-26T22:15:13","date_gmt":"2026-06-27T03:15:13","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/comparison-between-molecular-and-histological-idh-wild-type-glioblastoma-and-extensive-subgroup-analysis-of-idh-wild-type-astrocytic-tumors-without-genomic-glioblastoma-defining-alterations"},"modified":"2026-06-26T22:15:13","modified_gmt":"2026-06-27T03:15:13","slug":"comparison-between-molecular-and-histological-idh-wild-type-glioblastoma-and-extensive-subgroup-analysis-of-idh-wild-type-astrocytic-tumors-without-genomic-glioblastoma-defining-alterations","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/comparison-between-molecular-and-histological-idh-wild-type-glioblastoma-and-extensive-subgroup-analysis-of-idh-wild-type-astrocytic-tumors-without-genomic-glioblastoma-defining-alterations","title":{"rendered":"Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/comparison-between-molecular-and-histological-idh-wild-type-glioblastoma-and-extensive-subgroup-analysis-of-idh-wild-type-astrocytic-tumors-without-genomic-glioblastoma-defining-alterations.jpg\"><\/a><\/p>\n<p>This study compares clinical characteristics and survival between molecular (MolGBM) and histological <i>IDH<\/i>-wild-type (<i>IDH<\/i>-WT) glioblastoma (HistGBM), and further characterizes histological lower-grade <i>IDH<\/i>-WT astrocytic tumors without genomic GBM-defining alterations.<\/p>\n<p>Adult patients with histologically lower-grade <i>IDH\u2013<\/i>WT astrocytoma (WHO grade 2\u20133) and available tumor tissue were included. Tumors were classified according to the 2021 WHO Classification of CNS tumors. Biopsy-only cases were excluded. <i>IDH1<\/i> and <i>TERT<\/i> promoter (<i>TERT<\/i>p) mutations were analyzed via Sanger and whole-exome sequencing (WES). <i>TERT<\/i>p-WT tumors underwent WES and subsequent DNA methylation profiling. Clinical, molecular, and outcome data were collected.<\/p>\n<p>The cohort comprised 47 surgically resected histologically lower-grade <i>IDH<\/i>-WT astrocytic tumors. Thirty-nine fulfilled WHO 2021 criteria for MolGBM, mainly based on <i>TERT<\/i>p mutation (<i>n<\/i> = 36), while eight lacked GBM-defining molecular alterations. Compared with HistGBM (<i>n<\/i> = 54), MolGBM more frequently presented with seizures and showed a lower Ki-67 index. Median overall survival (OS) was 19.8 months in MolGBM and 14.6 months in HistGBM, without a significant difference in univariable analysis (<i>p<\/i> = 0.11). Patients aged \u2265 60 years showed longer overall survival in the MolGBM group (17.9 vs. 12.3 months; <i>p<\/i> = 0.0079). In multivariable Cox regression adjusted for age, extent of resection, and completion of the Stupp regimen, MolGBM was independently associated with more favorable OS (HR 0.40, 95% CI 0.24\u20130.67, <i>p<\/i> = 0.0005). The eight tumors lacking GBM-defining alterations showed longer survival and marked diagnostic heterogeneity.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This study compares clinical characteristics and survival between molecular (MolGBM) and histological IDH-wild-type (IDH-WT) glioblastoma (HistGBM), and further characterizes histological lower-grade IDH-WT astrocytic tumors without genomic GBM-defining alterations. Adult patients with histologically lower-grade IDH\u2013WT astrocytoma (WHO grade 2\u20133) and available tumor tissue were included. Tumors were classified according to the 2021 WHO Classification of CNS [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-239739","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=239739"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239739\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=239739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=239739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=239739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}